Azucena Arévalo-Galvis

Azucena Arévalo-Galvis

Auto-generated profile, based on publicly available information

Azucena Arévalo-Galvis

Affiliation Departamento de Microbiología, Grupo de Enfermedades Infecciosas, Laboratorio de Bacteriología Especial, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 July 2016 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ATAlba A. Trespalacios-Rangél
Alba A. Trespalacios-Rangél
WOWilliam Otero
William Otero
AAAzucena Arévalo-Galvis
Azucena Arévalo-Galvis
Raúl Poutou-PiñalesRaúl Poutou-Piñales
Raúl Poutou-Piñales
EREmiko Rimbara
Emiko Rimbara
DGDavid Y. Graham
David Y. Graham
Increased resistance of Helicobacter pylori to clarithromycin and metronidazole has resulted in recommendation to substitute fluoroquinolones for eradication therapy. The aims of the study were to determine the prevalence and changes in primary levofloxacin resistance related to H. pylori gyrA sequences. The study utilized H. pylori strains isolated from patients undergoing gastroscopy in Bogotá, Colombia from 2009 to 2014. Levofloxacin susceptibility was assessed by agar dilution. Mutations in gyrA sequences affecting the quinolone resistance-determining region (QRDR) were evaluated by direct sequencing. Overall, the mean prevalence of primary levofloxacin resistance was 18.2% (80 of 439 samples). Resistance increased from 11.8% (12/102) in 2009 to 27.3% (21/77) in 2014 (p = 0.001). gyrA mutations in levofloxacin resistant strains were present in QRDR positions 87 and 91. The most common mutation was N87I (43.8%, 35/80) followed by D91N (28.8%, 23/80) and N87K (11.3%, 9/80). Levofloxacin resistance increased markedly in Colombia during the six-year study period. Primary levofloxacin resistance was most often mediated by point mutations in gyrA, with N87I being the most common QRDR mutation related to levofloxacin resistance.

30 August 2013 in Journal of Microbiology
Verified
Journal Article
Closed access
PDF file
ATAlba A. Trespalacios
Alba A. Trespalacios
WOWilliam Otero
William Otero
JCJorge E. Caminos
Jorge E. Caminos
MMMarcela M. Mercado
Marcela M. Mercado
JÁJenny Ávila
Jenny Ávila
DGDavid Y. Graham
David Y. Graham
Resistance of Helicobacter pylori to clarithromycin is the most common cause of treatment failure in patients with H. pylori infections. This study describes the MICs and the presence of 23S rRNA mutations of H. pylori isolates from Bogotá, D.C., Colombia. H. pylori were isolated from gastric biopsies from patients with functional dyspepsia. Clarithromycin susceptibility was investigated by agar dilution and strains were considered resistant if the MIC was ≥1 μg/ml. DNA sequences of the 23S rRNA gene of strains resistant and sensitive to clarithromycin were determined to identify specific point mutations. Clarithromycin resistance was present in 13.6% of patients by agar dilution. The A2143G, A2142G and A2142C mutations were found in 90.5, 7.1, and 2.4% of H. pylori strains with resistance genotype.The resistant phenotype was associated with 23S rRNA resistance genotype in 85.7% of isolates. The point mutations in 23S rRNA were well correlated with MICs values for clarithromycin.

1 January 2012 in Polish Journal of Microbiology
Verified
Journal Article
Closed access
AAAzucena Arévalo-Galvis
Azucena Arévalo-Galvis
ATAlba A. Trespalacios-Rangel
Alba A. Trespalacios-Rangel
WOWilliam Otero
William Otero
MMMarcela M. Mercado-Reyes
Marcela M. Mercado-Reyes
Raúl Poutou-PiñalesRaúl Poutou-Piñales
Raúl Poutou-Piñales
The clinical outcome of Helicobacter pylori infection has been particularly associated with virulence genotypes. These genotypes are useful as molecular markers in the identification of patients that are infected and at high risk for developing more severe gastric pathologies. Our main objective was to determine the prevalence of virulence genotypes cagA, vacA, iceA and babA2 of H. pylori, in patients with functional dyspepsia who are infected with the bacteria. H. pylori genotypes babA2 and cagA as well as vacA and iceA allelic variants were identified by PCR in 122 isolates resulting from 79 patients with functional dyspepsia. A high prevalence of genes cagA+ (71%), vacAs1am1 (34%), babA2 (57%) and iceA1 (87%) was found. The most frequent combined genotype found were cagA+/vacAs1am1/babA2+/iceA1 and cagA-/vacAs1am1/babA2+/iceA1, regardless of any family history of gastric cancer or MALT lymphoma. The very virulent genotype cagA+/vacAs1am1/babA2+/iceA1 prevailed in the studied patients with functional dyspepsia. Our results provide information about the prevalence of four of the more important virulent factors and constitute new evidence on the prevalence of the most virulent H. pylori genotype in patients with functional dyspepsia.

11 March 2019 in Helicobacter
Verified
Journal Article
Open access
PDF file
AGAzucena Arévalo Galvis
Azucena Arévalo Galvis
ARAlba Alicia Trespalacios Rangel
Alba Alicia Trespalacios Rangel
WRWilliam Otero Regino
William Otero Regino
Background: Triple therapy efficacy against Helicobacter pylori is low worldwide, and thus, alternatives must be sought to improve eradication. The aim of the present study was to determine CYP2C19 genetic polymorphism effect on H pylori eradication.Methods: A randomized, single‐blinded clinical trial including 133 participants was carried out. H pylori infection was confirmed by histologic and microbiologic test. Antibiotic susceptibility to amoxicillin and clarithromycin was performed. CYP2C19 polymorphisms *1, *2, and *3 were analyzed by real‐time PCR (Roche ®), and nested PCR for CYP2C19*17 polymorphisms. Participants were randomized into two groups for different H pylori therapies, one with standard omeprazole doses and another with omeprazole doses depending on CYP2C19 polymorphism. H pylori eradication was verified by stool antigen tests (Meridian ®).Results: The most common CYP2C19 polymorphism was *1/*1 in 54.9% of the participants followed by *17/*17 in 21.1%. Triple therapy efficacy with standard omeprazole doses versus personalized therapy based on CYP2C19 polymorphism by ITT analysis was 84% (95% CI: 0.73‐0.91) vs 92.2% (95% CI: 0.82‐0.97) (P = 0. 14), respectively. The efficacy by PP analysis was 92.1% (95% CI: 0.82‐0.97) vs 100% (95% CI: 0.92‐0.01) (P = 0.027), respectively.Conclusions: The most frequent polymorphism was extensive PPI metabolizers (62.4%). Effectiveness of guided therapies by susceptibility test was good, yet they can be further improved by customized therapy based on CYP genotype. Therefore, high PPI (80 mg/d) doses are recommended for H pylori eradication therapies in Colombia.ClinicalTrials.gov ID: NCT03650543.

20 November 2017 in Enzyme Research
Verified
Journal Article
Open access
PDF file
DNDoris C. Niño-Gómez
Doris C. Niño-Gómez
CRClaudia M. Rivera-Hoyos
Claudia M. Rivera-Hoyos
EMEdwin David Morales-Álvarez
Edwin David Morales-Álvarez
EMEdgar Antonio Reyes Montaño
Edgar Antonio Reyes Montaño
NVNury E. Vargas-Alejo
Nury E. Vargas-Alejo
AAAzucena Arévalo-Galvis
Azucena Arévalo-Galvis
Phytases are used for feeding monogastric animals, because they hydrolyze phytic acid generating inorganic phosphate.Aspergillus niger3-phytase A (PDB: 3K4Q) and 3-phytase B (PDB: 1QFX) were characterized using bioinformatic tools. Results showed that both enzymes have highly conserved catalytic pockets, supporting their classification as histidine acid phosphatases. 2D structures consist of 43% alpha-helix, 12% beta-sheet, and 45% others and 38% alpha-helix, 12% beta-sheet, and 50% others, respectively, and pI 4.94 and 4.60, aliphatic index 72.25 and 70.26 and average hydrophobicity of −0,304 and −0.330, respectively, suggesting aqueous media interaction. Glycosylation and glycation sites allowed detecting zones that can affect folding and biological activity, suggesting fragmentation. Docking showed thatH59andH63act as nucleophiles and thatD339andD319are proton donor residues. MW of 3K4Q (48.84 kDa) and 1QFX (50.78 kDa) is similar; 1QFX forms homodimers which will originate homotetramers with several catalytic center accessible to the ligand. 3K4Q is less stable (instability index 45.41) than 1QFX (instability index 33.66), but the estimated lifespan for 3K4Q is superior. Van der Waals interactions generate hydrogen bonds between the active center and O2or H of the phytic acid phosphate groups, providing greater stability to these temporal molecular interactions.

1 May 2019 in Biomédica
Verified
Journal Article
Closed access
PDF file
AAAzucena Arévalo
Azucena Arévalo
WOWilliam Alberto Otero
William Alberto Otero
ATAlba Alicia Trespalacios
Alba Alicia Trespalacios
Introducción. La resistencia a los antibióticos es la principal causa del fracaso del tratamiento contra Helicobacter pylori; la claritromicina y el metronidazol son los antibióticos que generan mayor resistencia. En Colombia, la resistencia primaria a estos dos antibióticos y el uso excesivo de levofloxacina han alcanzado los límites aceptados (13,6, 83 y 16 %, respectivamente). A pesar de ello, se usa el tratamiento empírico combinando estos antibióticos en pacientes en los que ha fallado anteriormente.Objetivo. Determinar la resistencia a los antibióticos en pacientes previamente tratados para H. pylori en Bogotá, Colombia.Materiales y métodos. Se llevó a cabo un estudio descriptivo en el que se evaluó mediante dilución en agar la resistencia a la amoxicilina, la claritromicina, la levofloxacina y el metronidazol en 10 aislamientos provenientes de 5 pacientes con tres o cuatro tratamientos fallidos para H. pylori. La resistencia a los antibióticos se confirmó mediante secuenciación de ADN (Magrogen, Korea).Resultados. Ocho de los aislamientos presentaron resistencia a dos o más antibióticos y todos fueron resistentes a la levofloxacina. Los patrones de sensibilidad de los aislamientos provenientes del antro pilórico y del cuerpo del estómago, fueron diferentes en tres de los pacientes.Conclusión. Hasta donde se sabe, esta es la primera evidencia de resistencia múltiple de H. pylori en Colombia en pacientes previamente tratados. Los resultados evidenciaron las consecuencias del uso de un esquema ineficaz de tratamiento antibiótico y la necesidad de evaluar la sensibilidad a los antibióticos en diferentes sitios anatómicos del estómago. La resistencia múltiple limita el número de antibióticos útiles para erradicar H. pylori.